Haleon plc Form 6-K Summary
Business Context and Reporting Period
Haleon plc, a global consumer-health company listed on the LSE and NYSE, filed this Form 6-K for March 2024. The filing reports a capital and voting-rights update dated 21 March 2024. Haleon’s key categories include oral health, pain relief, respiratory health, digestive health, and vitamins, minerals and supplements.
Key Financial and Capital Metrics
- On 21 March 2024, Haleon cancelled 102,272,727 ordinary shares of £0.01 each that had been repurchased from Pfizer Inc.
- Total issued ordinary shares with voting rights after the cancellation: 9,132,301,104.
- Ordinary shares held in treasury: none.
- The filing does not provide revenue, profit, cash flow, margins, debt, liquidity, or other operating-financial metrics.
Material Changes and Outlook
The material reported change is the cancellation of the shares repurchased from Pfizer Inc., reducing the company’s issued share count. The filing does not provide guidance, an earnings outlook, management commentary on operating performance, contingencies, or unusual financial items.
Important Facts to Verify
- Verify the post-cancellation voting-rights denominator of 9,132,301,104 shares for FCA disclosure-notification calculations.
- Confirm that no ordinary shares were held in treasury as of 21 March 2024.
- Review subsequent filings for additional share repurchases, cancellations, changes in Pfizer’s ownership, or updates to total voting rights.
- Use Haleon’s annual report or earnings disclosures for financial performance, leverage, liquidity, and guidance information not included in this filing.